Previous 10 | Next 10 |
Submitted a Special Protocol Assessment to the FDA for Phase III program evaluating vilobelimab in Hidradenitis Suppurativa (HS) in Q1 2021 Phase III trial in Severe COVID-19 is ongoing and recruiting patients Topline data from Phase II US trial in ANCA-Associated Vasculitis expec...
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at two upcoming virtual investor conferences. H.C. Wainwright Global Life Sciences Confe...
JENA, Germany, March 01, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has completed its underwritten public offering of 15,000,000 common...
Gainers: Pandion Therapeutics (PAND) +132%, Dynatronics (DYNT) +68%, ChromaDex (CDXC) +30%, ASLAN Pharmaceuticals (ASLN) +28%, Brookdale Senior Living (BKD) +22%.Losers: U.S. Physical Therapy (USPH) -21%, CollPlant Biotechnologies (CLGN)&...
Clinical-stage biopharmaceutical company InflaRx N.V. (IFRX) announces the pricing of its underwritten public offering of 15M shares and warrants, with the shares priced at $5/share, leading to expected gross proceeds of $75M.For each share bought, investors will also receive a warr...
JENA, Germany, Feb. 25, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the pricing of its underwritten public offering of 15,000,000 common shares ...
IT Tech Packaging (ITP) -23% on stock offering.Ping Identity Holding (PING) -14% on Q4 results.ReTo Eco-Solutions (RETO) -10%.United States Antimony (UAMY) -9%.BioCryst Pharmaceuticals (BCRX) -9% on Q4 earnings.Best Buy (BBY) -7% on Q4 results.Chimerix (CMRX) -7% on Q...
InflaRx (IFRX) traded 9.9% down after hours on commencing an underwritten public offering of shares; for each common share purchased, an investor will also receive a warrant to purchase a share.Net proceeds to be used mainly for funding research and development expenses for its clin...
JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has commenced an underwritten public offering of common shares of th...
Significantly elevated baseline C5a levels occur in hidradenitis suppurativa (HS) patients Vilobelimab dose-dependently suppresses C5a levels over time accompanied by the previously reported reduction in inflammatory lesion counts and scores Data support continued development of v...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...